Professor of Oncology, Johns Hopkins University School of Medicine; Associate Professor of Oncology
Oncology
Dr. Ephraim J. Fuchs, MD
|
|
Give Review
Ephraim Fuchs practices Oncology. He attended Perelman School of Medicine at the University of Pennsylvania. He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Ephraim J. Fuchs is also a published doctor. He has 80 publication published. The most recent publication is: Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Ephraim Fuchs accepts Medicare payments and is listed with Medicare.gov.
Publications
- Anti-CD45 radioimmunotherapy without TBI before BMT facilitates persistent haploidentical donor enGraftment in a murine model.
- Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
- Post-transplantation cyclophosphamide as single-agent GVHD prophylaxis after myeloablative conditioning and HLA-matched allografting for Acute leukemias and myelodyspl...
- Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies.
- Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in adv...
- HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation.
- Transplantation tolerance: from theory to clinic.
- Aldehyde dehydrogenase expression drives human regulatory T Cell resistance to posttransplantation cyclophosphamide.
- Selective allodepletion: have we finally found the Holy Grail?
- Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-vers...
- Alternative transplant donor sources: is there any consensus?
- Outcomes of Related Donor HLA-Identical or HLA-Haploidentical Allogeneic Blood or Marrow Transplantation for Peripheral T Cell Lymphoma.
- Partially Mismatched Transplantation and Human Leukocyte Antigen Donor-Specific Antibodies.
- Human leukocyte antigen-haploidentical stem cell transplantation using T-cell-replete bone marrow Grafts.
- Human leukocyte antigen-haploidentical hematopoietic stem Cell transplant for a patient with histiocytic sarcoma.
- 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.
- Alternative donor transplantation: results of parallel phase II trials using HLA-mismatched related bone marrow or unrelated umbilical cord blood Grafts.
- High-dose cyclophosphamide for Graft-versus-host disease prevention.
- High-dose, post-transplantation cyclophosphamide to promote Graft-host tolerance after allogeneic hematopoietic stem cell transplantation.
- Cryoimmunotherapy in urologic oncology.
- High-dose cyclophosphamide as single-agent, short-course prophylaxis of Graft-versus-host disease.
- Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marro...
- Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.
- High-dose cyclophosphamide for severe aplastic Anemia: long-term follow-up.
- HLA-haploidentical stem Cell transplantation for hematologic malignancies.
- Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation.
- Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic Cell transplantation following nonmyeloablative conditioning for ...
- HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
- The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T Cells.
- Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk Lymphoma.
- Factors governing the activation of adoptively transferred donor T Cells infused after allogeneic bone marrow transplantation in the mouse.
- Host-derived Langerhans cells persist after MHC-matched alloGrafting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocy...
- Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions.
- Resistance of Cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochond...
- Bone marrow transplantation for sickle cell Anemia: progress and prospects.
- Association of Foxp3 regulatory gene expression with Graft-versus-host disease.
- The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human Leukemia.
- Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell Anemia and beta-thalassemia.
- Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple Myeloma: importance of allogeneic T cells.
- Nonmyeloablative alternative donor transplants.
- Successful therapy of metastatic Cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.
- Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation.
- Posttransplantation cyclophosphamide facilitates enGraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total bo...
- Recent developments in HLA-haploidentical transplantations.
- Neonatal tolerance revisited: turning on newborn T Cells with dendritic Cells.
- B Cells turn off virgin but not memory T Cells.
- Balancing justice and autonomy in clinical research with healthy volunteers.
- Accelerator mass spectrometry measurement of intraCellular concentrations of active drug metabolites in human target Cells in vivo.
- Quantitative imaging and sigmoidoscopy to assess distribution of rectal microbicide surrogates.
- Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers.
- Is cancer dangerous to the immune System?
- Payment to healthy volunteers in clinical research: the research subject's perspective.
- Autologous renal cell Cancer vaccines using heat shock protein-peptide complexes.
- Salvage transplantation for alloGraft failure using fludarabine and alemtuzumab as conditioning regimen.
- Hematopoietic stem Cell transplant as a platform for tumor immunotherapy.
- High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell Lymphomas.
- Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell Lymphoma.
- Hematopoietic stem cell transplantation for chronic lymphocytic Leukemia.
- Selective radiosensitization of p53-deficient Cells by caffeine-mediated activation of p34cdc2 kinase.
- Flavopiridol induces apoptosis in chronic lymphocytic Leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.
- CD95 (Fas)-induced caspase-mediated proteolysis of NF-kappaB.
- Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic Anemia.
- Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem Cells.
- p53-mediated repression of nuclear factor-kappaB RelA via the transcriptional integrator p300.
- Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT.
- Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.
- Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for Acute myeloid leukaemia beyond first remission: a 10-year experience.
- Myeloablative allogeneic bone marrow transplant using T cell depleted alloGrafts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.
- Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB.
- Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide.
- Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide.
- Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic Diseases.
- Role of allogeneic transplantation for FLT3/ITD Acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.
- Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate Graft-versus-host reactions.
- Cytotoxic T Cells overcome BCR-ABL-mediated resistance to apoptosis.
- p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32beta.
- Durable enGraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and p...
- Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell Anemia.
- Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide.
Schools
Perelman School of Medicine University of Pennsylvania
Johns Hopkins Hospital
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Central Nervous System Lymphoma
- Coagulation Disorders (incl. Hemophilia)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Johns Hopkins University -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
Johns Hopkins Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1578506135 |
| Last Name Of The Provider | FUCHS |
| First Name Of The Provider | EPHRAIM |
| View All |
Similar Doctors
|
|
Dr. Leisha A. Emens, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hyam I. Levitsky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward A. Sausville, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. David D. Sidransky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ivan M. Borrello, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laurence A. Doyle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diana H. Griffiths, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rosalyn A. Juergens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronan J. Kelly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mya S. Thein, MD
This Doctor is OpenDoctor Recommended.
|